Grossman Adam S's Form 4 filing
Adma Biologics, Inc. (ADMA) · filed Jul 16, 2025
- Accession no.
- 0001140361-25-026099
- Filed
- Jul 16, 2025
- Trade date
- Jul 15, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $391.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grossman Adam SCIK 0001542517 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2025 | Common Stock | MOption exerciseAcquired | +15,000 | $5.40 | +$81,000 | 2,058,850 | Direct | |
| Jul 15, 2025 | Common Stock | SSaleDisposed | −15,000 | $18.66F2 | −$279,900 | 2,043,850 | Direct | |
| Jul 15, 2025 | Common Stock | SSaleDisposed | −6,000 | $18.66F2 | −$111,960 | 2,037,850 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2025 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 795,950 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is the price at which the shares were sold.
Referenced by the price of 2 transactions in Table I.